Target Name: WNT9A
NCBI ID: G7483
Review Report on WNT9A Target / Biomarker Content of Review Report on WNT9A Target / Biomarker
WNT9A
Other Name(s): Wnt-9a | WNT9A_HUMAN | wingless-type MMTV integration site family, member 14 | Wingless-type MMTV integration site family, member 9A | Protein Wnt-9a | Wingless-type MMTV integration site family, member 14 | wingless-type MMTV integration site family, member 9A | Protein Wnt-14 | Wnt family member 9A | WNT14

WNT9A: A Potential Drug Target and Biomarker

Introduction

Wnt-9a, also known as WNT-9A, is a non-coding RNA molecule that plays a crucial role in the development and maintenance of tissues and organs, including neural cells and tissues. Wnt-9a is a key regulator of the Wnt signaling pathway, which is involved in the regulation of cell proliferation, differentiation, and survival. The Wnt signaling pathway has been implicated in various diseases, including cancer, neurodegenerative diseases, and developmental disorders. Therefore, targeting Wnt-9a has the potential to be a valuable drug or biomarker for the treatment of these diseases.

Clinical Significance of WNT-9a

Wnt-9a has been shown to be involved in the development and maintenance of various tissues and organs, including neural cells and tissues. Studies have shown that Wnt-9a plays a critical role in the development and progression of neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease, and Huntington's disease. Wnt-9a has also been shown to be involved in the regulation of cancer cell proliferation and survival. Therefore, targeting Wnt-9a may have potential therapeutic applications for these diseases.

Drug Targeting Wnt-9a

One potential approach to targeting Wnt-9a is to use small molecules or antibodies that can inhibit the activity of Wnt-9a. Small molecules that inhibit the activity of Wnt-9a include inhibitors of the Wnt-9a signaling pathway, such as 灏?-actinin , which is a protein that plays a role in the regulation of Wnt-9a. Antibodies that recognize and target Wnt-9a include monoclonal antibodies (MAs), which are laboratory-produced antibodies that can be used to detect and measure the level of Wnt-9a in a particular tissue or cell.

Biomarker Analysis

Another approach to targeting Wnt-9a is to use biomarkers that are derived from Wnt-9a. One potential biomarker for Wnt-9a is the protein known as Wnt-9a-specific protein (WSP), which is a protein that is expressed in high levels in neural tissues and is involved in the regulation of Wnt-9a signaling. Another potential biomarker for Wnt-9a is the RNA molecule known as microRNA-20 (miRNA-20), which is a non-coding RNA molecule that is involved in the regulation of various gene expressions, including the regulation of Wnt-9a.

Conclusion

Wnt-9a is a non-coding RNA molecule that plays a crucial role in the development and maintenance of tissues and organs, including neural cells and tissues. The Wnt signaling pathway has been implicated in various diseases, including cancer, neurodegenerative diseases, and developmental diseases disorders. Therefore, targeting Wnt-9a has the potential to be a valuable drug or biomarker for the treatment of these diseases. The use of small molecules or antibodies that inhibit the activity of Wnt-9a, or the use of biomarkers that are derived from Wnt-9a, may be a promising approach to targeting Wnt-9a. Further research is needed to fully understand the role of Wnt-9a in various diseases and to develop effective treatments.

Protein Name: Wnt Family Member 9A

Functions: Ligand for members of the frizzled family of seven transmembrane receptors. Functions in the canonical Wnt/beta-catenin signaling pathway. Required for normal timing of IHH expression during embryonic bone development, normal chondrocyte maturation and for normal bone mineralization during embryonic bone development. Plays a redundant role in maintaining joint integrity

The "WNT9A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about WNT9A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

WNT9B | WRAP53 | WRAP73 | WRN | WRNIP1 | WSB1 | WSB2 | WSCD1 | WSCD2 | WSPAR | WT1 | WT1-AS | WTAP | WTAPP1 | WTIP | WWC1 | WWC2 | WWC2-AS2 | WWC3 | WWOX | WWP1 | WWP2 | WWTR1 | WWTR1-AS1 | XAB2 | XACT | XAF1 | XAGE-4 | XAGE1A | XAGE1B | XAGE1D | XAGE2 | XAGE3 | XAGE5 | XBP1 | XCL1 | XCL2 | XCR1 | XDH | XG | XGY2 | XIAP | XIRP1 | XIRP2 | XIST | XK | XKR3 | XKR4 | XKR5 | XKR6 | XKR7 | XKR8 | XKR9 | XKRX | XKRY | XKRYP7 | XLOC_007697 | XLOC_008559 | XLOC_009911 | XNDC1N | XPA | XPC | XPC complex | XPNPEP1 | XPNPEP2 | XPNPEP3 | XPO1 | XPO4 | XPO5 | XPO6 | XPO7 | XPOT | XPR1 | XRCC1 | XRCC2 | XRCC3 | XRCC4 | XRCC5 | XRCC6 | XRCC6P5 | XRN1 | XRN2 | XRRA1 | XXYLT1 | XXYLT1-AS2 | XYLB | XYLT1 | XYLT2 | YAE1 | YAF2 | YAP1 | YARS1 | YARS2 | YBEY | YBX1 | YBX1P1 | YBX1P10 | YBX1P2 | YBX1P4 | YBX2